Real-world effectiveness of omalizumab in severe allergic asthma: a meta-analysis of observational studies
J Bousquet, M Humbert, PG Gibson, K Kostikas… - The Journal of Allergy …, 2021 - Elsevier
Background Assessment of clinical outcomes in the real-world corroborates findings from
randomized controlled trials (RCTs). Objective This meta-analysis evaluated real-world data …
randomized controlled trials (RCTs). Objective This meta-analysis evaluated real-world data …
“Real-life” effectiveness studies of omalizumab in adult patients with severe allergic asthma: meta-analysis
A Alhossan, CS Lee, K MacDonald… - The Journal of Allergy and …, 2017 - Elsevier
Background After the approval of omalizumab for severe allergic asthma, a total of 25
studies have evaluated the effectiveness of omalizumab under “real-life” conditions of …
studies have evaluated the effectiveness of omalizumab under “real-life” conditions of …
Short-and long-term real-world effectiveness of omalizumab in severe allergic asthma: systematic review of 42 studies published 2008-2018
Introduction: Omalizumab is a recombinant monoclonal anti-IgE antibody approved in the
US as add-on treatment in moderate-to-severe allergic asthma (in severe allergic asthma …
US as add-on treatment in moderate-to-severe allergic asthma (in severe allergic asthma …
'Real‐life'effectiveness studies of omalizumab in adult patients with severe allergic asthma: systematic review
I Abraham, A Alhossan, CS Lee, H Kutbi… - Allergy, 2016 - Wiley Online Library
Abstract We reviewed 24 'real‐life'effectiveness studies of omalizumab in the treatment of
severe allergic asthma that included 4117 unique patients from 32 countries with significant …
severe allergic asthma that included 4117 unique patients from 32 countries with significant …
[HTML][HTML] Real-world safety and efficacy of omalizumab in patients with severe allergic asthma: a long-term post-marketing study in Japan
M Adachi, M Kozawa, H Yoshisue, KL Milligan… - Respiratory …, 2018 - Elsevier
Abstract Background Omalizumab (anti-IgE monoclonal antibody) is an approved add-on
therapy for Japanese patients with severe allergic asthma. As directed by the Ministry of …
therapy for Japanese patients with severe allergic asthma. As directed by the Ministry of …
Omalizumab in patients with severe asthma: the XCLUSIVE study
C Schumann, C Kropf, T Wibmer… - The clinical …, 2012 - Wiley Online Library
Abstract Background and Aims: Although the efficacy and safety of omalizumab (OMA) in
uncontrolled severe allergic asthma has been demonstrated in several randomised …
uncontrolled severe allergic asthma has been demonstrated in several randomised …
[HTML][HTML] The eXpeRience registry: the 'real-world'effectiveness of omalizumab in allergic asthma
GJ Braunstahl, CW Chen, R Maykut, P Georgiou… - Respiratory …, 2013 - Elsevier
Omalizumab has demonstrated therapeutic benefits in controlled clinical trials. Evaluation of
outcomes in real-world clinical practice is needed to provide a complete understanding of …
outcomes in real-world clinical practice is needed to provide a complete understanding of …
Omalizumab in severe allergic asthma inadequately controlled with standard therapy: a randomized trial
NA Hanania, O Alpan, DL Hamilos… - Annals of internal …, 2011 - acpjournals.org
Background: Inhaled corticosteroids (ICS) and long-acting β2-agonists (LABAs) are
recommended in patients with asthma that is not well-controlled; however, many patients …
recommended in patients with asthma that is not well-controlled; however, many patients …
[HTML][HTML] Longterm clinical outcomes of omalizumab therapy in severe allergic asthma: study of efficacy and safety
AH Mansur, S Srivastava, V Mitchell, J Sullivan… - Respiratory …, 2017 - Elsevier
Omalizumab has been shown to be an effective add-on therapy for patients with
uncontrolled severe persistent allergic asthma. There has been a steady accumulation of …
uncontrolled severe persistent allergic asthma. There has been a steady accumulation of …
[HTML][HTML] Predicting and evaluating response to omalizumab in patients with severe allergic asthma
BACKGROUND: Omalizumab is a monoclonal antibody indicated for treatment of severe
persistent allergic asthma inadequately controlled despite optimal controller therapy. We …
persistent allergic asthma inadequately controlled despite optimal controller therapy. We …